Jenkoo (@Jenkoool) profile picture

AIM Investor

Joined February 2022
Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)Photo by Jenkoo (@Jenkoool)
Wtf is this share price action. #avct Very frustrating. Given the progress, LTH’s should be sat on a comfortable profit having shouldered the risk. Really disappointing performance.
4
2
44
2,770
The market cap of #avct represents fantastic risk/reward. Which is both positive as I’m buying, but frustrating as I want to see value being attributed to the superb tech and ongoing de-risking.
9
1,031
This is the best part of the RNS #avct ❤️🥇 incredible: ‘Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment 1/2
2
10
1
60
4,059
Does this mean that Avacta can administer AVA6103 to FAPlow expression and create a higher FAP environment which further compounds the resovoir affect?!? #avct
1
5
46
1,409
Transcriptomic analysis via RNA seq studies revealed that AVA6103 induced a coordinated inflammatory, wound-healing response, with an upregulation of pathways involved with damage repair, cell cycle arrest, and extracellular matrix (ECM) reorganisation’ 2/2
1
2
29
733
My thoughts: *CC was excellent again. Discussing complexity with clarity & terminology that was absorbing for all. *confidence was high. 6103 readout being a close match to pre-clinical was the standout moment of the presentation for me. They must be seeing efficacy 1/4 #avct
1
3
28
2,068
*6103 will take patient care to the next level. 6207 will be a whole new game, especially in hard to treat settings. *opportunity remains gigantic. More patience required. Board are in control & holding firm. BP will respect their IP & there resolve. 3/4 #avct
1
1
12
1,301
*6000 feels ‘side of desk’ with 6103 performing (maybe rightly so). Potentially BP feel the same. *this time next year Rodney 👏🏻 Happy investor. SP is an opportunity, but must raise significantly through next year or unanswered commercial Q’s will be brought to a head 4/4 #avct
1
1
1
11
3,217
‘This Fundraise demonstrates tremendous confidence in Avacta’ I find it hard to agree with that in honesty. A discounted raise on an already deflated SP doesn’t demonstrate tremendous confidence imo. I could agree if the raise was at a premium… #avct
4
1
27
2,415
Slept on it & still disappointed. #avct Ben captures my thoughts well. A good post. fear for 6k is that nobody wants to deal at any decent value, as a next gen dox would wipe the floor (capping +pre|C +linker +dox) 🤔 Feels like an all or nothing crescendo on 6103 efficacy
3
12
2,004
6103 PK RNS followed by suspension & raise in order to value to markets appetite would have created the most value opportunity. Shame it wasn’t capitalised on. Anyway… life as an #avct SH goes on. Exciting times ahead remain on track ❤️
5
1,013
Something caused this pivot to suspension & raise imo. Otherwise, #avct would have surely suspended on the same day as releasing the 6103 announcement on 25th. This would have created a potential scramble for shares at unknown SP. Likely at a decent premium. 1/2
1
7
2,797
If they thought the SP would rise post-announcement in the hope to raise with lower dilution; they would have done so closer to the announcement. Personally I suspect #avct were not happy with the best offer, given efficacy is still ‘a risk for BP’ due to not yet being confirmed
2
1
2,110
If I’m reading right, cash burn was £5m per month July & August. Likely due to trial setup inc manufacturing + bond. Assuming that continues, cash sits at circa £7m hence the raise. If they want to raise into tail of H1, I suspect this will be hefty . Needs to inc bond #avct 1/3
2
3
2,062
I see this as another example of #avct SH’s being victim of the co’s success. Clearly BoD see more value in further data validation given the positive PK&PD of 6103. I don’t disagree. This is biotech & I trust BoD to extract max value long term. Only shame is the Likely £price
1
4
1,272
Ultimately whilst 6103 continues to push the boundaries, there are unknowns. Ie- unknown value of the asset. Until that is better understood, #avct will not deal, as every bit of data is seemingly increasing BP’s price. 3/3 All imo of course 👍🏻
8
1,144
During 6k trials, partial responses were RNS’d as they occurred. This almost certainly won’t be the case for 6103. Imo, we get the 6103 efficacy data & Partner announcement on the same day across 2 RNS towards the tail end of H1. 6k & 6207 partners…. Who knows 🤷‍♂️ 1/2 #avct
3
1
9
3,037
Are BP holding back 6k deals until 6103 efficacy data is shared? Are #avct delaying 6k deals in hope the 6103 efficacy increases 6k and platform value? How does a partner manage the conflict of 6103 & 6207 target overlap? There are many questions 🧚🏻‍♂️ 🦁 🩻 #faridox #beast 2/2
1
2
11
2,051
Having listened to the spotlight episode again… I realise I missed that some of the prior treatment patients were given Enhertu. Getting efficacy data in patients who stopped taking Enhertu (likely due to MLD or DLT’s) would be a noteworthy point for the FDA 🤔 #avct
1
34
2,154